Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function
Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represe...
Gespeichert in:
| Veröffentlicht in: | Anti-cancer drugs 2002-09, Vol.13 (8), p.847-849 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 849 |
|---|---|
| container_issue | 8 |
| container_start_page | 847 |
| container_title | Anti-cancer drugs |
| container_volume | 13 |
| creator | Bauer, Sebastian Hagen, Volker Pielken, Hermann J Bojko, Peter Seeber, Siegfried Schütte, Jochen |
| description | Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of choice for GIST, is primarily metabolized by the liver, data on the pharmacokinetics and the tolerability of imatinib in patients with increased cholestasis parameters are not yet available. We here report on two patients who received imatinib in the presence of increased bilirubin and/or cholestasis parameters. With a follow-up duration of 3–4 months, we observed no toxicities outside of well-known side effects including some degree of myelosuppression and fluid retention. This report may aid in the decision of imatinib being given under close surveillance to this kind of patients. |
| doi_str_mv | 10.1097/00001813-200209000-00010 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00001813_200209000_00010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12394270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3560-439e6b834faa7845e446667047f25391a682ca69c57522bb5fd54d0ea7272b563</originalsourceid><addsrcrecordid>eNp1kctOwzAQRS0EoqXwC8g_EPAzjpeo4lGpEhtYW04yoYa8ZDtU_XtcWmDFbEZz595ZnEEIU3JDiVa3JBUtKM8YIYzoNGV7hZygORWKZ1IJeormREudCa34DF2E8J4sSefnaEYZ14IpMkfNqrPR9a7EHYRdayPguAFvxx12PR7TDvoY8NbFDX6zIfrB9RFCitgW78cu9Th1gw_Y9jV23Widhxq37hM8bqa-im7oL9FZY9sAV8e-QK8P9y_Lp2z9_Lha3q2zisucZIJryMuCi8ZaVQgJQuR5rohQDZNcU5sXrLK5rqSSjJWlbGopagJWMcVKmfMFKg53Kz-E4KExo3ed9TtDidmjMz_ozC86840uRa8P0XEqO6j_gkdWySAOhu3QRvDho5224M0GbBs35r-X8C-IQnpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>Bauer, Sebastian ; Hagen, Volker ; Pielken, Hermann J ; Bojko, Peter ; Seeber, Siegfried ; Schütte, Jochen</creator><creatorcontrib>Bauer, Sebastian ; Hagen, Volker ; Pielken, Hermann J ; Bojko, Peter ; Seeber, Siegfried ; Schütte, Jochen</creatorcontrib><description>Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of choice for GIST, is primarily metabolized by the liver, data on the pharmacokinetics and the tolerability of imatinib in patients with increased cholestasis parameters are not yet available. We here report on two patients who received imatinib in the presence of increased bilirubin and/or cholestasis parameters. With a follow-up duration of 3–4 months, we observed no toxicities outside of well-known side effects including some degree of myelosuppression and fluid retention. This report may aid in the decision of imatinib being given under close surveillance to this kind of patients.</description><identifier>ISSN: 0959-4973</identifier><identifier>EISSN: 1473-5741</identifier><identifier>DOI: 10.1097/00001813-200209000-00010</identifier><identifier>PMID: 12394270</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins, Inc</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Benzamides ; Enzyme Inhibitors - therapeutic use ; Gastrointestinal Neoplasms - drug therapy ; Gastrointestinal Neoplasms - pathology ; Humans ; Imatinib Mesylate ; Male ; Middle Aged ; Piperazines - adverse effects ; Piperazines - therapeutic use ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Stromal Cells - pathology</subject><ispartof>Anti-cancer drugs, 2002-09, Vol.13 (8), p.847-849</ispartof><rights>2002 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3560-439e6b834faa7845e446667047f25391a682ca69c57522bb5fd54d0ea7272b563</citedby><cites>FETCH-LOGICAL-c3560-439e6b834faa7845e446667047f25391a682ca69c57522bb5fd54d0ea7272b563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12394270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bauer, Sebastian</creatorcontrib><creatorcontrib>Hagen, Volker</creatorcontrib><creatorcontrib>Pielken, Hermann J</creatorcontrib><creatorcontrib>Bojko, Peter</creatorcontrib><creatorcontrib>Seeber, Siegfried</creatorcontrib><creatorcontrib>Schütte, Jochen</creatorcontrib><title>Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function</title><title>Anti-cancer drugs</title><addtitle>Anticancer Drugs</addtitle><description>Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of choice for GIST, is primarily metabolized by the liver, data on the pharmacokinetics and the tolerability of imatinib in patients with increased cholestasis parameters are not yet available. We here report on two patients who received imatinib in the presence of increased bilirubin and/or cholestasis parameters. With a follow-up duration of 3–4 months, we observed no toxicities outside of well-known side effects including some degree of myelosuppression and fluid retention. This report may aid in the decision of imatinib being given under close surveillance to this kind of patients.</description><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Gastrointestinal Neoplasms - pathology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - therapeutic use</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Stromal Cells - pathology</subject><issn>0959-4973</issn><issn>1473-5741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctOwzAQRS0EoqXwC8g_EPAzjpeo4lGpEhtYW04yoYa8ZDtU_XtcWmDFbEZz595ZnEEIU3JDiVa3JBUtKM8YIYzoNGV7hZygORWKZ1IJeormREudCa34DF2E8J4sSefnaEYZ14IpMkfNqrPR9a7EHYRdayPguAFvxx12PR7TDvoY8NbFDX6zIfrB9RFCitgW78cu9Th1gw_Y9jV23Widhxq37hM8bqa-im7oL9FZY9sAV8e-QK8P9y_Lp2z9_Lha3q2zisucZIJryMuCi8ZaVQgJQuR5rohQDZNcU5sXrLK5rqSSjJWlbGopagJWMcVKmfMFKg53Kz-E4KExo3ed9TtDidmjMz_ozC86840uRa8P0XEqO6j_gkdWySAOhu3QRvDho5224M0GbBs35r-X8C-IQnpg</recordid><startdate>200209</startdate><enddate>200209</enddate><creator>Bauer, Sebastian</creator><creator>Hagen, Volker</creator><creator>Pielken, Hermann J</creator><creator>Bojko, Peter</creator><creator>Seeber, Siegfried</creator><creator>Schütte, Jochen</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200209</creationdate><title>Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function</title><author>Bauer, Sebastian ; Hagen, Volker ; Pielken, Hermann J ; Bojko, Peter ; Seeber, Siegfried ; Schütte, Jochen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3560-439e6b834faa7845e446667047f25391a682ca69c57522bb5fd54d0ea7272b563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Gastrointestinal Neoplasms - pathology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - therapeutic use</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Stromal Cells - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bauer, Sebastian</creatorcontrib><creatorcontrib>Hagen, Volker</creatorcontrib><creatorcontrib>Pielken, Hermann J</creatorcontrib><creatorcontrib>Bojko, Peter</creatorcontrib><creatorcontrib>Seeber, Siegfried</creatorcontrib><creatorcontrib>Schütte, Jochen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anti-cancer drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bauer, Sebastian</au><au>Hagen, Volker</au><au>Pielken, Hermann J</au><au>Bojko, Peter</au><au>Seeber, Siegfried</au><au>Schütte, Jochen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function</atitle><jtitle>Anti-cancer drugs</jtitle><addtitle>Anticancer Drugs</addtitle><date>2002-09</date><risdate>2002</risdate><volume>13</volume><issue>8</issue><spage>847</spage><epage>849</epage><pages>847-849</pages><issn>0959-4973</issn><eissn>1473-5741</eissn><abstract>Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of choice for GIST, is primarily metabolized by the liver, data on the pharmacokinetics and the tolerability of imatinib in patients with increased cholestasis parameters are not yet available. We here report on two patients who received imatinib in the presence of increased bilirubin and/or cholestasis parameters. With a follow-up duration of 3–4 months, we observed no toxicities outside of well-known side effects including some degree of myelosuppression and fluid retention. This report may aid in the decision of imatinib being given under close surveillance to this kind of patients.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>12394270</pmid><doi>10.1097/00001813-200209000-00010</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4973 |
| ispartof | Anti-cancer drugs, 2002-09, Vol.13 (8), p.847-849 |
| issn | 0959-4973 1473-5741 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00001813_200209000_00010 |
| source | Journals@Ovid Ovid Autoload; MEDLINE |
| subjects | Aged Antineoplastic Agents - therapeutic use Benzamides Enzyme Inhibitors - therapeutic use Gastrointestinal Neoplasms - drug therapy Gastrointestinal Neoplasms - pathology Humans Imatinib Mesylate Male Middle Aged Piperazines - adverse effects Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - adverse effects Pyrimidines - therapeutic use Stromal Cells - pathology |
| title | Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A10%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imatinib%20mesylate%20therapy%20in%20patients%20with%20gastrointestinal%20stromal%20tumors%20and%20impaired%20liver%20function&rft.jtitle=Anti-cancer%20drugs&rft.au=Bauer,%20Sebastian&rft.date=2002-09&rft.volume=13&rft.issue=8&rft.spage=847&rft.epage=849&rft.pages=847-849&rft.issn=0959-4973&rft.eissn=1473-5741&rft_id=info:doi/10.1097/00001813-200209000-00010&rft_dat=%3Cpubmed_cross%3E12394270%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12394270&rfr_iscdi=true |